Scientist man in white gowns stands in a research lab

Research

Science can improve health and wellbeing in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines.

As GSK and through our heritage companies, we have a 150-year legacy of applying science to discover and develop new medicines, vaccines and consumer healthcare products that help to transform lives.

More than 11,000 people work in R&D in our search for new medicines, vaccines and consumer healthcare products.

A Canadian R&D Leader

Canada's Top 100 Corporate R&D Spenders 2018

GlaxoSmithKline Inc. (GSK) is one of the largest research and development (R&D) organizations in Canada. GSK invested more than $68 million in Canadian research and development (R&D) in 2017, ranking it among the top 40 contributors to R&D in Canada, across all industries.

Clinical Studies

  • In 2018, GSK invested over $ 15 million into 54 active clinical trials across Canada involving 2,793 active subjects.
  • In 2018, GSK supported 15 Investigator Sponsored Studies with physicians across Canada.
  • In 2018, GSK sponsored approximately 30 Canadian research projects fcoused on health economics and outcomes research to support the scientific understanding of our medicines and vaccines in Canada.

Supporting R&D Innovation in Canada

To accelerate the discovery of new medicines and vaccines, we make collaboration part of our business model. Partnering with academic researchers and public organisations is a key part of our research efforts and we have a range of projects in place to allow us to work with and support new projects that fall within the specific areas of science we are interested in exploring.

In Canada, GSK is actively engaged in the support of research and innovation in the life sciences, and the commercialization of new technologies.  GSK works actively with academic researchers, university industry liaison and technology transfer offices, and innovation hubs such as MaRS Innovation, the Centre for Drug Research and Development (CDRD), NEOMED Institute and the Quebec Consortium for Drug Development (CQDM), to investigate new therapeutic targets as well as disruptive platforms for discovery and development.

Click here to see our current areas of interest.  For more information, please contact Amyn Sayani, (905) 819 3185 or Amyn.P.Sayani@gsk.com.

Find out about the main areas of science we are focusing on, how we conduct our research, what drives our R&D operations, and view our product pipeline.